From: Joern Loetsch j.loetsch@em.uni-frankfurt.de
Subject: [NMusers] NONMEM sparse data advantage reference
Date: Thu, 02 Nov 2006 07:22:31 +0100
Dear NONMEM users, The NONMEM approach is especially better than the
two-stage approach to estimate the PK of some drug in a sparse data
situation. Not speaking of its other advantages.
I fail to remember a reference for this.
Could you please help me out.
Thank you in advance.
Jrn Ltsch
--
_______________________________________________________
Univ.-Prof. Dr. med. Jrn Ltsch
pharmazentrum frankfurt/ZAFES
Institut fr Klinische Pharmakologie Johann Wolfgang Goethe-Universitt Theodor-Stern-Kai 7 D-60590 Frankfurt am Main
Tel.:069-6301-4589
Fax.:069-6301-7636
http://www.klinik.uni-frankfurt.de/zpharm/klin/
NONMEM sparse data advantage reference
From: Nitin Mehrotra nitin_utmem@yahoo.com
Subject: Re: [NMusers] NONMEM sparse data advantage reference
Date: Thu, 2 Nov 2006 06:52:21 -0800 (PST)
Dear Joern,
You might want to look at the following references:
1: Ette EI, Williams PJ, Lane JR.
Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies.
Ann Pharmacother. 2004 Dec;38(12):2136-44. Epub 2004 Oct 26. Review.
PMID: 15507495 [PubMed - indexed for MEDLINE]
2: Ette EI, Williams PJ.
Population pharmacokinetics II: estimation methods.
Ann Pharmacother. 2004 Nov;38(11):1907-15. Epub 2004 Sep 14. Review.
PMID: 15367729 [PubMed - indexed for MEDLINE]
3: Ette EI, Williams PJ.
Population pharmacokinetics I: background, concepts, and models.
Ann Pharmacother. 2004 Oct;38(10):1702-6. Epub 2004 Aug 24. Review.
PMID: 15328391 [PubMed - indexed for MEDLINE]
Warm Regards
Nitin Mehrotra
Dept. Pharmaceutical Sciences
UTHSC, Memphis, TN
_______________________________________________________